309 related articles for article (PubMed ID: 12595259)
1. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin.
Richards J; Miller M; Abend J; Koide A; Koide S; Dewhurst S
J Mol Biol; 2003 Mar; 326(5):1475-88. PubMed ID: 12595259
[TBL] [Abstract][Full Text] [Related]
2. Backbone dynamics of homologous fibronectin type III cell adhesion domains from fibronectin and tenascin.
Carr PA; Erickson HP; Palmer AG
Structure; 1997 Jul; 5(7):949-59. PubMed ID: 9261088
[TBL] [Abstract][Full Text] [Related]
3. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells.
Lanza P; Felding-Habermann B; Ruggeri ZM; Zanetti M; Billetta R
Blood Cells Mol Dis; 1997 Aug; 23(2):230-41. PubMed ID: 9268674
[TBL] [Abstract][Full Text] [Related]
4. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
Mould AP; Craig SE; Byron SK; Humphries MJ; Jowitt TA
Biochem J; 2014 Dec; 464(3):301-13. PubMed ID: 25333419
[TBL] [Abstract][Full Text] [Related]
5. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain.
Batori V; Koide A; Koide S
Protein Eng; 2002 Dec; 15(12):1015-20. PubMed ID: 12601141
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human α
Borst AJ; James ZM; Zagotta WN; Ginsberg M; Rey FA; DiMaio F; Backovic M; Veesler D
Structure; 2017 Nov; 25(11):1732-1739.e5. PubMed ID: 29033288
[TBL] [Abstract][Full Text] [Related]
7. Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects.
Son HN; Nam JO; Kim S; Kim IS
Biochim Biophys Acta; 2013 Oct; 1833(10):2378-88. PubMed ID: 23792174
[TBL] [Abstract][Full Text] [Related]
8. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain.
Koide A; Koide S
Methods Mol Biol; 2007; 352():95-109. PubMed ID: 17041261
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin.
Van Agthoven JF; Xiong JP; Alonso JL; Rui X; Adair BD; Goodman SL; Arnaout MA
Nat Struct Mol Biol; 2014 Apr; 21(4):383-8. PubMed ID: 24658351
[TBL] [Abstract][Full Text] [Related]
10. The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3.
Yu J; Lee CY; Changou CA; Cedano-Prieto DM; Takada YK; Takada Y
Biochem J; 2017 Feb; 474(4):589-596. PubMed ID: 27993971
[TBL] [Abstract][Full Text] [Related]
11. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.
Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A
Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200
[TBL] [Abstract][Full Text] [Related]
12. Distinct structural requirements for interaction of the integrins alpha 5 beta 1, alpha v beta 5, and alpha v beta 6 with the central cell binding domain in fibronectin.
Chen J; Maeda T; Sekiguchi K; Sheppard D
Cell Adhes Commun; 1996 Nov; 4(4-5):237-50. PubMed ID: 9117344
[TBL] [Abstract][Full Text] [Related]
13. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.
Silverman AP; Levin AM; Lahti JL; Cochran JR
J Mol Biol; 2009 Jan; 385(4):1064-75. PubMed ID: 19038268
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin.
Spitaleri A; Mari S; Curnis F; Traversari C; Longhi R; Bordignon C; Corti A; Rizzardi GP; Musco G
J Biol Chem; 2008 Jul; 283(28):19757-68. PubMed ID: 18480047
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin type III domain based monobody with high avidity.
Duan J; Wu J; Valencia CA; Liu R
Biochemistry; 2007 Nov; 46(44):12656-64. PubMed ID: 17929945
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
Chen N; Leu SJ; Todorovic V; Lam SC; Lau LF
J Biol Chem; 2004 Oct; 279(42):44166-76. PubMed ID: 15308622
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization and comparison of RGD cell-adhesion recognition sites engineered into streptavidin.
Le Trong I; McDevitt TC; Nelson KE; Stayton PS; Stenkamp RE
Acta Crystallogr D Biol Crystallogr; 2003 May; 59(Pt 5):828-34. PubMed ID: 12777798
[TBL] [Abstract][Full Text] [Related]
18. Cyclic RGD and
Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
[TBL] [Abstract][Full Text] [Related]
19. Interdomain tilt angle determines integrin-dependent function of the ninth and tenth FIII domains of human fibronectin.
Altroff H; Schlinkert R; van der Walle CF; Bernini A; Campbell ID; Werner JM; Mardon HJ
J Biol Chem; 2004 Dec; 279(53):55995-6003. PubMed ID: 15485890
[TBL] [Abstract][Full Text] [Related]
20. Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin.
Iida J; Skubitz AP; Furcht LT; Wayner EA; McCarthy JB
J Cell Biol; 1992 Jul; 118(2):431-44. PubMed ID: 1629241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
